Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
398 stopped studies mapped to Sarcoma and descendants · 90% state a reason
Over the 398 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03132155 | QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma | Phase 2 | terminated | Apr 27, 2017 | NantPharma, LLC | Prematurely terminated due to lack of therapeutic effect | Other (stated, no rule matched) |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | — | terminated | Jul 2, 2019 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Lack of recruitment | Enrollment / accrual |
| NCT05043649 | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Phase 1 | terminated | Sep 14, 2021 | Monopar Therapeutics | lack of timely enrollment | Enrollment / accrual |
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase 1 | terminated | Sep 13, 2018 | Fred Hutchinson Cancer Center | The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was… | Enrollment / accrual |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Phase 1 | terminated | May 26, 2021 | Pyramid Biosciences | Sponsor terminated development of PBI-200 | Other (stated, no rule matched) |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Phase 1 | terminated | Nov 1, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT02706171 | Stereotactic Radiosurgery for Soft Tissue Sarcoma | N/A | withdrawn | Mar 11, 2016 | The Cooper Health System | not stated | Not stated |
| NCT04900766 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone… | Phase 1 | terminated | May 25, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT03711279 | A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma | Phase 2 | terminated | Oct 18, 2018 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT04553744 | Identification of Surgical Management of Lymph Node Basins and Surgical Practice Patterns… | — | withdrawn | Sep 17, 2020 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft…(Tolerance) | Phase 3 | terminated | Mar 3, 2021 | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawal grant provider | Other (stated, no rule matched) |
| NCT04176016 | Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory… | Phase 1 | terminated | Nov 25, 2019 | OncoTherapy Science, Inc. | Some of the raw materials for the investigational drug are difficult to obtain and expensive. | Other (stated, no rule matched) |
| NCT04274023 | Study on TSR-042 in Advanced Clear Cell Sarcoma(ACCeSs) | Phase 2 | terminated | Feb 18, 2020 | Italian Sarcoma Group | Difficulty of enrollment | Enrollment / accrual |
| NCT05238831 | SMMART Adaptive Clinical Treatment (ACT) Trial | Early Phase 1 | withdrawn | Feb 14, 2022 | OHSU Knight Cancer Institute | Withdrawn due to a change in therapeutic interventions. | Other (stated, no rule matched) |
| NCT05262101 | Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma | Phase 2 | terminated | Mar 2, 2022 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | The sponsor has decided to terminate this study based on the current clinical research status of… | Other (stated, no rule matched) |
| NCT05154630 | Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced… | Phase 1 / Phase 2 | terminated | Dec 13, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The sponsor has decided to terminate this study based on the current clinical research status of… | Other (stated, no rule matched) |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT00089245 | Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or… | Phase 1 | terminated | Aug 5, 2004 | Y-mAbs Therapeutics | Corporate business decision. No safety or efficacy concerns. | Safety / toxicity |
| NCT02940041 | Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal…(CERTUM) | — | terminated | Oct 20, 2016 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not enough patients included | Other (stated, no rule matched) |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | Phase 2 | terminated | Nov 11, 2021 | Benjamin Izar | Study terminated by PI | Other (stated, no rule matched) |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | Phase 1 / Phase 2 | terminated | Mar 8, 2018 | Bayer | no anticipated benefit over available standard therapies | Other (stated, no rule matched) |
| NCT04365660 | 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma | Phase 2 | terminated | Apr 28, 2020 | Davidzon, Guido, M.D. | lack of accrual with no intent of continuing | Enrollment / accrual |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03240861 | Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative…(NYESO SCT) | Phase 1 | terminated | Aug 7, 2017 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women… | Phase 4 | withdrawn | Sep 16, 2005 | Imperial College London | Recruitment not possible worldwide | Enrollment / accrual |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | Phase 2 | withdrawn | Dec 30, 2021 | David Liebner, MD | PI decision | Other (stated, no rule matched) |
| NCT03860207 | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in… | Phase 1 / Phase 2 | terminated | Mar 1, 2019 | Y-mAbs Therapeutics | study terminated due to business priorities | Sponsor / business decision |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial… | Phase 1 / Phase 2 | terminated | Oct 31, 2019 | Eli Lilly and Company | Study terminated for meeting protocol specified futility criteria. | Efficacy / futility |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric… | Phase 1 | terminated | Aug 31, 2015 | AeRang Kim | low accrual | Enrollment / accrual |
| NCT01367301 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | N/A | terminated | Jun 7, 2011 | Albert Einstein College of Medicine | Lack of accrual. PI left the institution | Investigator |
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With… | N/A | terminated | Oct 9, 2013 | Albert Einstein College of Medicine | Study terminated due to low accrual. PI left the institution | Investigator |
| NCT05026502 | A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of…(REACH) | — | terminated | Aug 30, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With… | Phase 1 / Phase 2 | terminated | Nov 10, 2008 | City of Hope Medical Center | Terminated early due a shift in resources after lackluster performance of the drug. | Other (stated, no rule matched) |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT04190433 | Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline… | Phase 2 | withdrawn | Dec 9, 2019 | Mayo Clinic | Administratively closed due to low/no accrual | Enrollment / accrual |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | N/A | terminated | Aug 29, 2019 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03495921 | A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With…(VITA) | Phase 3 | terminated | Apr 12, 2018 | Gradalis, Inc. | Slow accrual and as a result, a strategic business decision was made to terminate enrollment. | Enrollment / accrual |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors… | — | withdrawn | Dec 23, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer,… | N/A | terminated | Aug 15, 2018 | Roswell Park Cancer Institute | Diagnostic issues | Other (stated, no rule matched) |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT03867188 | Liposomal Bupivacaine (Exparel) in Sarcomas | Early Phase 1 | terminated | Mar 7, 2019 | Wake Forest University Health Sciences | Enrollment of eligible subjects, delays due to the COVID-19 Virus, and lack of funding | COVID-19 / pandemic |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT04877587 | Gemcitabine With Ascorbate Including Adolescents | Early Phase 1 | withdrawn | May 7, 2021 | David Dickens | Unable to enroll | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 24, 2024source: clinicaltrials